Log in

Relevant bibliographies by topics / Thrombo-Prophylaxis / Journal articles

To see the other types of publications on this topic, follow the link: Thrombo-Prophylaxis.

Journal articles on the topic 'Thrombo-Prophylaxis'

Author: Grafiati

Published: 5 June 2025

Last updated: 24 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Thrombo-Prophylaxis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Verolino, Pasquale, Caterina Sagnelli, Roberto Grella, Giovanni Francesco Nicoletti, Antonello Sica, and Mario Faenza. "The Impact of Direct Oral Anticoagulant Prophylaxis for Thromboembolism in Thrombophilic Patients Undergoing Abdominoplastic Surgery." Healthcare 10, no. 3 (2022): 476. http://dx.doi.org/10.3390/healthcare10030476.

Full text

Abstract:

Congenital or acquired thrombophilia is observed in 10–15% of the general population; therefore, careful screening is carried out in patients at higher risk of venous thrombo-embolism (VTE). High risk of VTE is a contraindication in patients undergoing abdominoplasty. We evaluated rivaroxaban, an oral Xa inhibitor, with enoxaparin, a subcutaneously low molecular weight heparin (LMWH), in 48 female patients with documented thrombophilia, undergoing thrombo-prophylaxis after abdominoplasty. Patients were stratified into two groups according to thrombo-prophylaxis procedure: enoxaparin Group (n = 28) and rivaroxaban Group (n = 20). Hematologic outcomes were evaluated including VTE and hematoma. No episodes of VTE occurred in both groups; two patients during their course of enoxaparin presented severe hematoma for drainage and hemostasis revision. This study suggests that abdominoplasty, in patients with thrombophilia, in combination with thrombo-prophylaxis can be performed safely. Rivaroxaban was as effective as LMWH for preventing VTE, with only a moderate risk of clinically relevant bleeding. More research is needed to determine the optimal timing and duration of prophylaxis in patients undergoing plastic surgery.

APA, Harvard, Vancouver, ISO, and other styles

2

Kuttanchettiyar, Krishnakumar G., and Meer M. Chisthi. "Deep venous thrombosis after major abdominal surgeries: a tertiary level centre study." International Surgery Journal 5, no. 1 (2017): 267. http://dx.doi.org/10.18203/2349-2902.isj20175908.

Full text

Abstract:

Background: Deep venous thrombo-embolism is a proven major complication in the postoperative setup among the western population. Hence specific guidelines exist on thrombo-prophylaxis for surgical patients. The limited number of studies available on the Indian patients do not provide conclusive data regarding the incidence of postoperative thrombo-embolism. Also, Indian patients are not routinely given prophylactic anticoagulants in many settings still now. In this research, we studied the incidence of deep venous thrombosis among patients who underwent major abdominal surgeries, over a period of 2 years.Methods: This retrospective descriptive study was done on patients who underwent any sort of major abdominal surgery from the surgical wards of Government Medical College, Thiruvananthapuram, for 2 years. This data was used to analyses the incidence of and factors related to postoperative deep venous thrombo-embolism.Results: We studied a total of 334 patients who fulfilled the inclusion criteria. Among these patients, only 1.19% developed deep venous thrombosis during the post-operative period. Since no guidelines existed regarding the usage of thrombo-prophylaxis during that period, very few patients were found to have used any of the prophylactic measures.Conclusions: The incidence of postoperative deep venous thrombosis is not very high in the Indian population after major abdominal surgeries. This might be due to the relatively low prevalence of hyper-coagulable states in the community itself. As a corollary, routine chemical prophylaxis might be administered only in high risk patients. Other measures like early ambulation and mechanical prophylaxis might be used in patients with lesser risk.

APA, Harvard, Vancouver, ISO, and other styles

3

Letsky, Elizabeth A. "8 Peripartum prophylaxis of thrombo-embolism." Baillière's Clinical Obstetrics and Gynaecology 11, no. 3 (1997): 523–43. http://dx.doi.org/10.1016/s0950-3552(97)80026-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Azami, Milad, and Esmaiil Ghasemi Pashaklaee. "44: DETERMINATION OF FREQUENCY PERCENTAGE OF PROPHYLAXIS UTILIZATION AGAINST DEEP VEIN THROMBOSIS AMONG PATIENTS HOSPITALIZED IN DIFFERENT WARDS OF IMAM KHOMEINI TEACHING HOSPITAL." BMJ Open 7, Suppl 1 (2017): bmjopen—2016–015415.44. http://dx.doi.org/10.1136/bmjopen-2016-015415.44.

Full text

Abstract:

Background and aims:The current survey aims at determining the frequency percentage of Prophylaxis usage against deep vein thrombosis (DVT) according to ACCP instruction among the patients hospitalized in Imam Khomeini teaching hospital in Ilam.Methods:This study is descriptive and retrospective and the sampling was carried out amongst the cases of patients who were hospitalized and operated in the period occurred in March of 2012 to September of 2013 in Imam Khomeini hospital in Ilam. The type of receiving Prophylaxis was determined by ACCP (The American College of Chest Physicians) Guidelines. After investigating the input and output criteria, patients' data were extracted according to the dependent variables. Eventually the information gathered from the cases were analyzed by SPSS software version 17.Results:Studying 169 qualified cases from which 46.2% (78 participants) were female. Showed that from 132 patients needed to receive Prophylaxis only 39 persons (29.5%) were given Prophylaxis and according to ACCP Guidelines with respect to the appropriate type, dose, and duration of thromboprophylaxis was operated in only 30 individuals (22.5%) completely. The maximum rate of thrombo-prophylaxis happened to be in ICU (46.6%) and neurosurgery section (47.5%) and the least utilization of that was in the kidney and urinary tract section (0%).Conclusion:This study shows that there are a considerable difference in clinical performance recommended by ACCP in prophylaxis against DVT and in 75% of patients endangered by DVT, thrombo-prophylaxis according to ACCP Guidelines was not operated. Thus, new strategies must be implemented to operate thrombo-prophylaxis against DVT in Ilam hospitals.

APA, Harvard, Vancouver, ISO, and other styles

5

Kurtoglu, Mehmet, and Emre Sivrikoz. "Venous Thrombo-embolism prophylaxis: Intermittent pneumatic compression." Reviews in Vascular Medicine 1, no. 4 (2013): 71–75. http://dx.doi.org/10.1016/j.rvm.2013.08.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Madhubala, M., C. Kasthuri, Mansi Shukul, and J. Mohamed Ali. "Low dose unfractionated heparin with low dose aspirin in treatment of thrombo prophylaxis in utero placental insufficiency: a new vision in heparinization during pregnancy." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 7, no. 12 (2018): 4849. http://dx.doi.org/10.18203/2320-1770.ijrcog20184927.

Full text

Abstract:

Background: The use of heparin and aspirin in obstetric care has grown considerably since their introduction into clinical practice. Because of the physiological changes of pregnancy, the usage of heparin and optimal dosage of heparin remains uncertain. Here our institute designed low dose Unfractionated Heparin (5000 IU s/c daily) as thrombo Prophylaxis regimen. To study the outcome of low dose UFH (5000 IU sc /daily) + Low dose aspirin (75 mg oral per day) for thrombo prophylaxis in utero placental insufficiency, in patient with 2 or more abortions.Methods: This retrospective study was conducted in 135 patients with 2 or more abortions as obstetric history. Prophylactic low dose of UFH (5000 IU s/c daily) + LDA 75 mg oral was initiated. The Primary outcome is live birth, and secondary outcomes is Reduced incidence of early onset of gestational hypertension (HT), Intrauterine Growth Retardation (IUGR).Results: Out of 135 women 131 gave live birth, 2 had first trimester abortion and 2 had intrauterine death by 5 to 6 months. PIH was higher in patients with more than 30 years of age.Conclusions: In our Retrospective, data combination of low dose UFH (5000IU s/c) + LDA (75mg oral) is as safe as routine thrombo prophylaxis with good compliance.

APA, Harvard, Vancouver, ISO, and other styles

7

Efidi, R., J. Rimande, A. Agunloye, A. Ogunseyinde, R. Akinola, and G. Ogbole. "Sonographic Evaluation of Deep Vein Thrombosis in Hospitalized Neurosurgical Trauma Patients in Ibadan, Nigeria." Nigerian Journal of Clinical Practice 26, no. 12 (2023): 1833–38. http://dx.doi.org/10.4103/njcp.njcp_337_23.

Full text

Abstract:

Background: Deep vein thrombosis (DVT) is a major cause of morbidity and mortality in hospitalized trauma patients. Ultrasonography (US) has replaced venography as the initial diagnostic tool for DVT. Aims: The study aimed to determine the incidence of lower limb DVT in hospitalized neurosurgical trauma patients in hospitalized neurosurgical patients. It also aimed to determine the effect of combined thrombo-prophylaxis on the incidence of lower limb deep DVT relative to a single regimen. Patients and Methods: This was a prospective study of 154 adult neurotrauma patients who consecutively had lower limb Doppler ultrasound, initially within 72 hours of admissions and subsequently weekly or when DVT was suspected for the first 3 weeks of admission. The study spanned a 12-month period. The data generated were analyzed using the statistical package for social sciences software version 20, Chicago IL. Inc. Chi-square test was used to compare the outcome (DVT incidence) between single and combined prophylaxis groups. Results: The study participants consisted of 116 (75.3%) and 38 (24.7%) cases of head and spine injuries, respectively, with a mean age of 38.8 ± 6.3 years and 85.1% being males. A total of four cases of DVT were detected during the study period, with the majority of the cases (3) detected within the first week of admission, giving an incidence of 2.6%. All four cases of DVT were detected in patients on single thrombo-prophylaxis (4/55 = 7.3%), while none was found in those on a combined regimen (0/34, P = 0.046). Conclusion: Most cases of DVT developed in the first week of hospitalization. Combined thrombo-prophylaxis was more effective than single regimen at reducing rate of DVT in neurosurgical trauma patients. Routine Doppler ultrasound DVT surveillance should be part of the management protocol for neurosurgical trauma patients on admission to increase DVT detection and prevent possible fatal pulmonary embolism.

APA, Harvard, Vancouver, ISO, and other styles

8

Rafiq, Muhammad, Muhammad Rafiq, Maria Rafiq, Seema Salman, and Sania Hafeez. "Standard of surgical venous thrombo-prophylaxis in admitted patients." Archives of Clinical and Experimental Surgery (ACES) 6, no. 2 (2017): 1. http://dx.doi.org/10.5455/aces.20160324070821.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Torpiano, G., M. O'Boyle, and A. Gray. "Venous thrombo-embolic prophylaxis: Are standardised guidelines being followed?" International Journal of Surgery 55 (July 2018): S83. http://dx.doi.org/10.1016/j.ijsu.2018.05.393.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Muralikrishnan, Vummiti, J. Edwards, B. Sara, E. Davies, and P. Mekhail. "Is Systemic Thrombo-Embolic prophylaxis needed for Breast Surgery?" European Journal of Surgical Oncology (EJSO) 34, no. 10 (2008): 1177–78. http://dx.doi.org/10.1016/j.ejso.2008.06.103.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Turturiello, Dario, and Riccardo Cappato. "How much does the presentation pattern of atrial fibrillation affect thrombo-embolic risk and mortality?" European Heart Journal Supplements 25, Supplement_B (2023): B46—B49. http://dx.doi.org/10.1093/eurheartjsupp/suad066.

Full text

Abstract:

Abstract Atrial fibrillation (AF) is associated with a substantial increase in mortality and morbidity. Systemic thrombo-embolism is the most serious complication associated with this arrhythmia. The use of anticoagulant drugs is the cornerstone of therapy for the prophylaxis of stroke and peripheral ischaemia in these patients. The current guidelines recommend the use of anticoagulant drugs based on the thrombo-embolic risk profile of each individual patient calculated by SCORE based on the presence or absence of clinical risk factors and regardless of the presentation pattern of AF. A review of literature data investigating the effect of AF presentation pattern on thrombo-embolic risk and mortality showed an increased risk of both thrombo-embolic events and death in patients with non-paroxysmal AF compared to patients with paroxysmal AF. Most of these studies, however, consist of post-hoc analyses of large trials or observational studies and meta-analyses derived from these, resulting in an important limitation in the interpretation of data derived from such studies. At the same time, these data suggest the need for both new therapies to prevent AF progression and for further studies to explore the integration of AF presentation pattern into models of thrombo-embolic risk.

APA, Harvard, Vancouver, ISO, and other styles

12

Rosignoli, Florencia Agustina, and Fernando Lipovestky. "Pharmacological prophylaxis of choice in venous thromboembolic disease in major orthopedic surgery: aspirin vs LMWH and other anticoagulants." Interdisciplinary Rehabilitation / Rehabilitacion Interdisciplinaria 6 (January 1, 2026): 19. https://doi.org/10.56294/ri202619.

Full text

Abstract:

Introduction: Venous thromboembolic disease, deep vein thrombosis and pulmonary embolism are important causes of long-term morbidity and mortality, and are preventable. The risk of VTE is established in patients who will undergo major orthopedic surgery, given by factors such as the duration of surgery and reduced perioperative mobility.Studies show that without pharmacological thrombo prophylaxis, VTE rates are significant. For this reason, it is essential to establish an effective thrombo prophylaxis protocol to prevent VTE without significantly increasing the risk of bleeding. There is no evidence with strong results regarding the drug of choice for thrombo prophylaxis, but currently meta-analyses and systematic reviews establish aspirin as an effective, accessible and low-cost option, with low risk of postoperative bleeding in low-risk patients.Aspirin is an easy-to-administer drug, does not require blood monitoring and is well tolerated, with an excellent safety profile. However, there are some theories that newer oral agents may have higher risks of bleeding, such as major hemorrhages and complications from postsurgical wounds. Therefore, there is still considerable debate about which agents should be preferred in terms of effectiveness and lower risk of bleeding.Objectives: To establish the drug of choice for thromboprophylaxis in VTE in patients undergoing major orthopedic surgery.Materials and methods: A bibliographic search and analysis was carried out, only 15 articles were suitable for the research, articles from international databases such as PubMed, Scopus and Cinahl were used.Results: There were no significant differences in the risk of VTE (OR = 0.93; 95% CI: 0.69-1.26; p = 0.64), DVT (OR = 0.72; 95% CI: 0.43-1.20; p = 0.21) or PTE (OR = 1.13; 95% CI: 0.86-1.49; p = 0.38) between the groups that received LMWH prophylaxis and those that received aspirin. Nor were significant differences found in mortality (p = 0.30), bleeding (p = 0.22), or surgical wound complications (p = 0.85) between the two groups.Conclusion: aspirin is at least as safe and effective a drug for thromboprophylaxis as OACs and LMWH.

APA, Harvard, Vancouver, ISO, and other styles

13

Rai, Sanjay Kumar, VP Raman, Naveen Shejale, SS Wani, and Rohit Varma. "To Study The Efficacy And Safety Of Rivaroxaban In The Prevention Of Venous Thromboembolism (Vte) After Total Hip And Knee Arthroplasty." Trauma International 3, no. 2 (2017): 3–7. http://dx.doi.org/10.13107/ti.2017.v03i02.046.

Full text

Abstract:

Objective: Development of venous thrombo-embolism (VTE) including deep venous thrombosis (DVT) is a common complication after total hip and total knee Arthroplasty, pelvic fracture or long bone fractures especially in lower limb. Currently used drugs for DVT prophylaxis after these procedures have important limitations, including parenteral administration, and unpredictable plasma levels requiring frequent monitoring and dose adjustment leading to decreased patient compliance. In our study we used oral Rivaroxaban, which is one of the newer oral anticoagulants and is a direct factor Xa inhibitor that has demonstrated superior efficacy, compared to that of enoxaparin or any parenteral LMWH. Materials & Methods: In our study, 180 patients who underwent Total knee replacement (TKR) or Total hip replacement (THR) in our centre were included. They were put on oral Rivaroxaban, 10 mg once daily, started 6 hours after surgery and continued for 03 weeks in case of TKR and 6 weeks in case of THR. Results: Venous thrombo-embolism (VTE) and Deep vein thrombosis (DVT) are common complications after THR and TKR and cause a substantial burden to patients, healthcare providers, increase costs to the patients and increase both morbidity and mortality, if not addressed promptly. Currently available anticoagulants in the form of subcutaneous injection have limitations that lead to decreased compliance with DVT prophylaxis guidelines. Rivaroxaban which is oral 10 mg once daily has superior efficacy compared to enoxaparin or any parenteral LMWH for the prevention of the same and the patient compliance is also very good. There were no incidences of increased bleeding or wound infection in our study as compared to control group which were given subcutaneous enoxaparin. Key words: Venous thrombo-embolism, deep vein thrombosis, Total knee replacement, Total hip replacement, Rivaroxaban, DVT prophylaxis.

APA, Harvard, Vancouver, ISO, and other styles

14

Kakkar, VV, PJ Fok, WJ Murray, et al. "Heparin and dihydroergotamine prophylaxis against thrombo-embolism after hip arthroplasty." Journal of Bone and Joint Surgery. British volume 67-B, no. 4 (1985): 538–42. http://dx.doi.org/10.1302/0301-620x.67b4.4030846.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Joshi, Rajnish, Saurabh Saigal, Jai Sharma, and Dinesh Singh. "Thrombo-prophylaxis in acutely ill medical and critically ill patients." Indian Journal of Critical Care Medicine 18, no. 6 (2014): 382–91. http://dx.doi.org/10.4103/0972-5229.133902.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Thabut, Gabriel, Candice Estellat, Isabelle Boutron, Charles Marc Samama, and Philippe Ravaud. "Methodological issues in trials assessing primary prophylaxis of venous thrombo-embolism." European Heart Journal 27, no. 2 (2005): 227–36. http://dx.doi.org/10.1093/eurheartj/ehi587.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Bergqvist, David. "MODERN ASPECTS OF PROPHYLAXIS AND THERAPY FOR VENOUS THROMBO-EMBOLIC DISEASE." ANZ Journal of Surgery 68, no. 7 (1998): 463–68. http://dx.doi.org/10.1111/j.1445-2197.1998.tb04805.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Guryel, Enis, Rachel Pearce, Mark Rickman, and Martin Bircher. "Thrombo-prophylaxis in pelvic and acetabular trauma patients: a UK consensus?" International Orthopaedics 36, no. 1 (2011): 165–69. http://dx.doi.org/10.1007/s00264-011-1276-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Harper, M. W., T. Nokes, and P. M. Robbins. "An audit of current post operative thrombo-prophylaxis following cardiac surgery." European Journal of Anaesthesiology 23, Supplement 38 (2006): 35. http://dx.doi.org/10.1097/00003643-200605001-00102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Willis-Owen, C. A., K. M. Sarraf, A. E. Martin, and D. K. Martin. "Are current thrombo-embolic prophylaxis guidelines applicable to unicompartmental knee replacement?" Journal of Bone and Joint Surgery. British volume 93-B, no. 12 (2011): 1617–20. http://dx.doi.org/10.1302/0301-620x.93b12.27650.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Alalfy, Mahmoud, Ahmed Elgazzar, and Ahmed Hassan. "The importance of thrombo prophylaxis in pregnant women with Covid-19." Obstetrics & Gynecology International Journal 12, no. 4 (2021): 203. http://dx.doi.org/10.15406/ogij.2021.12.00577.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Opara, E., J. Gile, and J. Zaidi. "Inferior vena cava filter thrombo-prophylaxis in high-risk twin pregnancy." International Journal of Gynecology & Obstetrics 98, no. 1 (2007): 62–63. http://dx.doi.org/10.1016/j.ijgo.2006.11.027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Raslan, Ahmed M., Jeremy D. Fields, and Anish Bhardwaj. "Prophylaxis for Venous Thrombo-Embolism in Neurocritical Care: A Critical Appraisal." Neurocritical Care 12, no. 2 (2009): 297–309. http://dx.doi.org/10.1007/s12028-009-9316-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Frasinariu, Otilia-Elena, Violeta Streanga, Aniela Rugina, Irina Ciomaga, and Nistor Nicolai. "THROMBOEMBOLIC DISEASE IN CHILDREN (EPIDEMIOLOGY, ETIOPATHOGENY AND DIAGNOSIS) (I)." Romanian Journal of Pediatrics 65, no. 2 (2016): 145–49. http://dx.doi.org/10.37897/rjp.2016.2.2.

Full text

Abstract:

Thrombosis is the result of an imbalance between two complex systems: hemostasis and fibrinolysis. Although the incidence of thromboembolism is lower in children than in adults, the associated morbidity is clinically relevant. This paper summarizes the main risk factors – important in defining effective strategies for primary thrombo-prophylaxis in children at risk, the diagnostic criteria and the optimal therapeutic approach, which have mostly been extrapolated from the adult’s recommendations until now.

APA, Harvard, Vancouver, ISO, and other styles

25

Sartori, Michelangelo, Miriam Fiocca, Mario Soldati, Laura Borgese, Elisabetta Favaretto, and Benilde Cosmi. "Padua Prediction Score and Hospital-Acquired Proximal and Isolated Distal Deep Vein Thrombosis in Symptomatic Patients." Hematology Reports 16, no. 4 (2024): 568–78. http://dx.doi.org/10.3390/hematolrep16040055.

Full text

Abstract:

Background: Hospital-acquired deep vein thrombosis (DVT) is an important cause of morbidity and mortality. Objectives: The purpose of this study was to evaluate the prevalence of proximal lower limb DVT and isolated distal DVT (IDDVT) and their relationship to the Padua Prediction Score (PPS) in acutely ill, hospitalized patients. Methods: In a single-center cross-sectional study, all inpatients from medical departments with suspected lower-extremity DVT were evaluated with whole-leg ultrasonography during 183 days from 2016 to 2017. Results: Among the 505 inpatients (age 78.0 ± 13.3, females 59.2%) from medical departments, 204 (40.2%) had PPS ≥ 4, but only 54.4% of them underwent pharmacological thrombo-prophylaxis. Whole-leg ultrasonography detected 47 proximal DVTs (9.3%) and 65 IDDVTs (12.8%). Proximal DVT prevalence was higher in patients with high PPS vs. those with low PPS (12.7% vs. 7.0% p = 0.029, respectively), whereas IDDVT prevalence was similar in patients with high and low PPS (14.7% vs. 11.6% p = 0.311, respectively). The area under the receiver operating curve (AUC) for the PPS was 0.62 ± 0.03 for all DVTs, 0.64 ± 0.04 for proximal DVTs, and 0.58 ± 0.04 for IDDVTs. Conclusions: In hospitalized patients, IDDVT had similar prevalence regardless of PPS risk stratification. Adherence to thrombo-prophylaxis in patients was still far from optimal.

APA, Harvard, Vancouver, ISO, and other styles

26

Gnanalingham, Kanna K., and Jeremy P. Holland. "Attitudes to the use of prophylaxis for thrombo-embolism in neurosurgical patients." Journal of Clinical Neuroscience 10, no. 4 (2003): 467–69. http://dx.doi.org/10.1016/s0967-5868(03)00060-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Elizondo, Maria, Carlos Doti, Julio Bruetman, et al. "Efficacy of extended thrombo-prophylaxis in major abdominal surgery: What does the evidence show?" Thrombosis and Haemostasis 99, no. 06 (2008): 1104–11. http://dx.doi.org/10.1160/th07-12-0759.

Full text

Abstract:

SummaryVenous thromboembolism (VTE) is a frequent complication following major abdominal surgery. The use of low-molecular-weight heparins (LMWH) to prevent thrombotic events in these patients is a common and well documented practice. However, there is some controversy surrounding the duration of the prophylaxis, as it has been suggested that the risk persists for several weeks after surgery.The objective of this meta-analysis is to systematically review the clinical studies that compared safety and efficacy of extended use of LMWH (for three to four weeks after surgery) versus conventional in-hospital prophylaxis. An electronic data base search was performed. Only randomized, controlled studies were eligible. Data on the incidence of deep vein thrombosis (DVT), VTE and bleeding were extracted. Only three studies fulfilled the inclusion criteria. The indication for surgery was neoplastic disease in 70.6% (780/1104) of patients. The administration of extended LMWH prophylaxis significantly reduced the incidence of VTE, 5.93% (23/388) versus 13.6% (55/405), RR 0.44 (CI 95% 0.28 – 0.7); DVT 5.93% (23/388) versus 12.9% (52/402), RR 0.46 (CI 95% 0,29 – 0,74); proximal DVT 1% (4/388) versus 4.72% (19/402), RR 0.24 (CI 95% 0.09 – 0,67). We found no significant difference in major or minor bleeding between the two groups: 3.85% (21/545) in the extended thrombo-prophylaxis (ETP) group versus 3.48% (19/559) in the conventional prophylaxis group; RR 1.12 (CI 95% 0.61 – 2.06). There was no heterogeneity between the studies. We conclude that ETP with LMWH should be considered as a safe and useful strategy to prevent VTE in high-risk major abdominal surgery.

APA, Harvard, Vancouver, ISO, and other styles

28

Siboub, Mohamed. "Diagnosed cerebral cortical venous thrombosis after initiation of chemotherapy for Burkitt's lymphoma: a case report." Annales Africaines de Medecine 16, no. 2 (2023): e5136-e5139. http://dx.doi.org/10.4314/aamed.v16i2.15.

Full text

Abstract:

La thrombose veineuse cérébrale (TVC) dans le contexte du lymphome constitue un événement rare pouvant être grave et mettre en jeu le pronostic vital. L'évaluation des facteurs de risque pour une bonne stratification des patients est nécessaire avant tout traitement antitumoral. A travers cette observation rare et inhabituelle de TVC survenue après le début du traitement, nous attirons l’attention des praticiens sur l'intérêt d’une prophylaxie primaire des patients diagnostiqués avec lymphome à haut risque de maladie thrombo-embolique veineuse. Cerebral venous thrombosis in lymphoma is rare and can be serious and potentially fatal. Evaluation of risk factors for correct stratification is required before antitumor treatment. Initiation of chemotherapy for bulky tumors can induce thrombosis in unusual localizations, which can be a serious diagnostic and therapeutic problem.Through an unusual and rare observation, we insist on the importance of primary prophylaxis of patients diagnosed with lymphoma with high risk of venous thrombo-embolic disease.

APA, Harvard, Vancouver, ISO, and other styles

29

Blom, Ashley, Giles Pattison, Sarah Whitehouse, Adrian Taylor, and Gordon Bannister. "Early death following primary total hip arthroplasty: 1,727 procedures with mechanical thrombo-prophylaxis." Acta Orthopaedica 77, no. 3 (2006): 347–50. http://dx.doi.org/10.1080/17453670610046244.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Helen Troy, Alexandra Ameera, Martin Davey, and Deborah McNamara. "AB181. Venous thrombo-embolism prophylaxis on colorectal wards: a pilot audit of standard." Mesentery and Peritoneum 4 (March 2020): AB181. http://dx.doi.org/10.21037/map.2020.ab181.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Horsburgh, B., and V. Srinivasan. "1016 Is extended venous thrombo-embolism pharmacological prophylaxis required following laparoscopic radical prostatectomy?" European Urology Supplements 12, no. 1 (2013): e1016-e1017. http://dx.doi.org/10.1016/s1569-9056(13)61493-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Morrey, B. F. "Early death following primary total hip arthroplasty: 1,727 procedures with mechanical thrombo-prophylaxis." Yearbook of Orthopedics 2007 (January 2007): 118. http://dx.doi.org/10.1016/s0276-1092(08)70121-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Muscedere, John G., Louise Roberts, Julie Trpkovski, Carol Diemer, and Deborah Cook. "The Incidence and Prophylaxis of Venous Thrombo-Embolism in a Community Intensive Care Unit." Chest 126, no. 4 (2004): 876S. http://dx.doi.org/10.1378/chest.126.4_meetingabstracts.876s-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Greer, Ian A. "1 Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in obstetrics and gynaecology." Baillière's Clinical Obstetrics and Gynaecology 11, no. 3 (1997): 403–30. http://dx.doi.org/10.1016/s0950-3552(97)80019-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Uppal, Shitanshu, Enrique Hernandez, Moushumi Dutta, Vani Dandolu, Stephen Rose, and Ellen Hartenbach. "Prolonged postoperative venous thrombo-embolism prophylaxis is cost-effective in advanced ovarian cancer patients." Gynecologic Oncology 127, no. 3 (2012): 631–37. http://dx.doi.org/10.1016/j.ygyno.2012.08.032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Connors, J. M., and D. Farge-Bancel. "New progress in the treatment and prophylaxis of venous thrombo-embolism in cancer patients." JMV-Journal de Médecine Vasculaire 45, no. 1 (2020): 2. http://dx.doi.org/10.1016/j.jdmv.2019.12.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Wilson, NV, SK Das, VV Kakkar, et al. "Thrombo-embolic prophylaxis in total knee replacement. Evaluation of the A-V Impulse System." Journal of Bone and Joint Surgery. British volume 74-B, no. 1 (1992): 50–52. http://dx.doi.org/10.1302/0301-620x.74b1.1732265.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Halm, Josiah. "Improving VTE prophylaxis in hospitalized oncologic patients: Institutional impact VTE mentored QI project." Journal of Clinical Oncology 30, no. 34_suppl (2012): 148. http://dx.doi.org/10.1200/jco.2012.30.34_suppl.148.

Full text

Abstract:

148 Background: Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism affects hundreds of thousand Americans each year. Pulmonary embolism(PE), is the 3rd leading cause of hospital related death and the most common preventable cause of death in the United States. Cancer is associated with 6-fold increase in the risk of VTE. For those undergoing surgery, the risks of post-operative DVT and fatal PE are 2-3 times greater, respectively, for cancer patients than non-cancer patients. VTE prophylaxis is widely available and effective, but frequently underused. VTE prevention is of particular concern to oncologists. Evidence based oncology-specific guidelines are available from several organizations including American Society of Clinical Oncology (ASCO) to highlight the importance of prophylaxis in oncology patients. An Interdisciplinary team of pharmacists and hospitalists received an educational grant to implement a VTE mentored project in a large Comprehensive Academic Cancer Center in the Southern United States. There was anecdotal evidence and data to suggest adherence to thrombo-prophylaxis was suboptimal, with multiple departments and physicians having their "own" order sets of varying complexities. Performance data on VTE was not routinely being collected and data on hospital-acquired VTE events was not consistently collected and reported. To meet increasing financial, regulatory and the clinical challenge of harmonizing VTE prophylaxis in the institution, a multi-disciplinary team was formed to implement this VTE initiative. Methods: The QI methodology used was the Plan, Do, Study and Act (PDSA). Step 1. Draft a single VTE protocol using best evidence with input from all stakeholders that will be acceptable to most users. Step 2. Analyze the care delivery throughout the hospital Step 3. Set up performance tracking with IT support Step 4. Staggered introduction/education of the VTE protocol across departments/physicians Step 5. Implement and track through cycles of PDSA. Results: The institution went from having about 10 different VTE order sets to a single VTE order set that was a single page and was utilized by medical, surgical and emergency room and ICU physicians. This was embed in all admission, transfer and post op orders. Use of VTE prophylaxis order set went from an aggregate of 40.7 to 76.1%, 3 months after implementation of initiative. 26% percent of patient with no prophylaxis ordered had no contraindications checked. 60.9% and 16% of admitted patients were risk stratified as moderate or high risk respectively. Conclusions: 4 key findings from the implementation project led to improved rates of thrombo-prophylaxis. Prescribers are in the best position to understand all components of the VTE risk as well as contraindications and should be responsible for VTE risk assessment, as hitherto nurses were doing risk assessment and physicians were prescribing prophylaxis. New VTE order set provided a linked menu of appropriate prophylaxis options for each level of risk which the older sets did not do. Embedding VTE order set in admission/transfer and post op orders sets led to increase use. Efforts to raise VTE awareness should be ongoing, routinely monitored and included with other safety indicators such as falls etc and reported back to providers and appropriate medical staff and executive committees.

APA, Harvard, Vancouver, ISO, and other styles

39

Abraham, A., L. Hajipour, AR Innes, H. Phillips, and AW McCaskie. "Are National Guidelines for Total Hip Replacement in the UK Reflected in Practice?" Annals of The Royal College of Surgeons of England 88, no. 2 (2006): 108–15. http://dx.doi.org/10.1308/003588406x82943.

Full text

Abstract:

INTRODUCTION A cross-sectional study was performed to compare the practice of total hip replacement (THR) in the UK against national guidelines. MATERIALS AND METHODS A postal questionnaire was sent to all fellows of the British Orthopaedic Association. RESULTS Of the 1587 questionnaires sent out, 966 (60.9%) were returned. Of these, 706 (73.1%) were available for data collection and analysis. CONCLUSIONS Consensus was observed in several areas including the use of pre-admission clinics and modern cementing techniques. Facilities deemed necessary for THR surgery such as HDU/ITU back-up, ultra-clean air and dedicated orthopaedic wards are almost universally available. However, a lack of consensus is evident in many areas including the process of obtaining written consent, thrombo-embolic prophylaxis, duration of antibiotic prophylaxis, supervision of trainee surgeons and follow-up arrangements. The proliferation in the range of implants, particularly aimed at ‘younger’ patients, available to surgeons has once again been highlighted.

APA, Harvard, Vancouver, ISO, and other styles

40

El-Qutob, D., L. Alvarez-Arroyo, I. Barreda, et al. "High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis." Heart & Lung 53 (May 2022): 77–82. http://dx.doi.org/10.1016/j.hrtlng.2022.02.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Guryel, E., R. Pearce, M. Rickman, and M. Bircher. "A national survey on the management of thrombo-prophylaxis in pelvic and acetabular trauma patients." Injury Extra 40, no. 10 (2009): 217. http://dx.doi.org/10.1016/j.injury.2009.06.256.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Barjot, P., G. Beucher, Y. Linder, and M. Herlicoviez. "Resistance to activated protein C during pregnancy: low molecular weight heparin for obsteric thrombo prophylaxis." International Journal of Gynecology & Obstetrics 70 (2000): D74. http://dx.doi.org/10.1016/s0020-7292(00)81924-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Rogers, BA, S. Phillips, J. Foote, and KJ Drabu. "Is there adequate provision of venous thrombo-embolism prophylaxis following hip arthroplasty? An audit and international survey." Annals of The Royal College of Surgeons of England 92, no. 8 (2010): 668–72. http://dx.doi.org/10.1308/003588410x12699663904952.

Full text

Abstract:

INTRODUCTION The peak incidence of venous thrombo-embolism (VTE) occurs 3 weeks following hip arthroplasty surgery and current guidelines proposing VTE prophylaxis continuing for 4 weeks after surgery. This study first compares the duration of treatment and satisfaction between patients prescribed low molecular weight heparin (LMWH) and rivaroxaban, a new oral Factor Xa inhibitor, following elective hip arthroplasty; and second, surveys the duration of LMWH use in other units. SUBJECTS AND METHODS An international survey detailing the use of LMWH was performed. A prospective audit was performed of 100 hip replacements, with 50 prescribed 40 mg once daily of subcutaneous enoxaparin and subsequently 50 patients prescribed 10 mg once daily of oral rivaroxaban. The duration of treatment, patient satisfaction and complications for both cohorts was quantified and compared against published evidence-based guidelines. RESULTS The survey demonstrated that four out of 39 (10.2%) units that routinely prescribe LMWH do so for at least 4 weeks following surgery. The audit demonstrated that rivaroxaban afforded a superior mean duration of postoperative VTE prophylaxis (35 days vs 5.4 days; P < 0.05) and superior patient satisfaction. There was no difference in the incidence of bleeding, wound infection or thrombotic complications. CONCLUSIONS This study demonstrates that patients are exposed to an increased VTE risk following hip replacement surgery due to the inadequate prescription of LMWH. This is poor clinical practice, contrary to current evidence-based guidelines and has potential medicolegal implications. The prescription of rivaroxaban affords a superior patient compliance compared with subcutaneous LMWH, thus ensuring that patients receive VTE prophylaxis for the current recommend period of time.

APA, Harvard, Vancouver, ISO, and other styles

44

Hammami, Rania, Jihen Jdidi, Olfa Chakroun, et al. "Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes." PLOS ONE 17, no. 8 (2022): e0270195. http://dx.doi.org/10.1371/journal.pone.0270195.

Full text

Abstract:

Introduction There are no clear data about the incidence and the prophylactic strategies of arterial and venous thromboembolic events (TE) in COVID-19 ambulatory patients. Thus, we conducted this study to analyze thromboembolic complications in this setting and to assess thromboprophylaxis management and outcomes in the real life. Patients and methods This is an observational study including Covid-19 ambulatory patients. We assessed incidence of venous and arterial TE events as well as thromboprophylaxis outcomes and hemorrhagic complications. We defined high risk thrombo-embolic factor according to the Belgian guidelines which are the only guidelines that described thromboprophylaxis in COVID-19 ambulatory patients. Results We included 2089 patients with a mean age of 43±16 years. The incidence of 30 days venous and arterial TE complications in our cohort was 1%. Venous thromboembolic complications occurred in 0.8% and arterial thromboembolic complications occurred in 0.3%.We noted at least one high-risk TE factor in 18.5% of patients but thromboprophylaxis was prescribed in 22.5% of the cases, LMWH in 18.1%, and Rivaroxaban in 3.7%. Hemorrhagic events occurred in eight patients (0.3%): five patients showed minor hemorrhagic events and three patients showed major ones (0.14%). Conclusions Our study showed that the incidence of thromboembolic complications is very low in COVID-19 ambulatory patients. Paradoxically, there is an over prescription of thrombo-prophylaxis in this population.

APA, Harvard, Vancouver, ISO, and other styles

45

Lorini, Ferdinando Luca, Maria Di Matteo, Paolo Gritti, et al. "Coagulopathy and COVID-19." European Heart Journal Supplements 23, Supplement_E (2021): E95—E98. http://dx.doi.org/10.1093/eurheartj/suab100.

Full text

Abstract:

Abstract SARS-CoV-2 infection is associated with frequent thrombotic events, at the micro and macro-vascular level, due to the perpetuation of a state of hypercoagulability. The so-called ‘COVID-19 associated coagulopathy’ (CAC) represents a key aspect in the genesis of organ damage from SARS-CoV-2. The main coagulative alterations described in the literature are represented by high levels of D-dimer and fibrinogen. Although CAC has some common features with disseminated intravascular coagulation and sepsis-induced coagulopathy, there are important differences between these clinical pictures and the phenotype of CAC is unique. The pathogenesis of CAC is complex and is affected by the strong interconnection between the inflammatory system and coagulation, in the phenomenon of immunothrombosis and thrombo-inflammation. Several mechanisms come into play, such as inflammatory cytokines, neutrophils, the complement system as well as an alteration of the fibrinolytic system. Finally, an altered platelet function and especially endothelial dysfunction also play a central role in the pathophysiology of CAC. Heparin has several potential effects in CAC, in fact in addition to the anticoagulant effect, it could have a direct antiviral effect and anti-inflammatory properties. The high incidence of thrombo-embolic phenomena despite the use of antithrombotic prophylaxis have led some experts to recommend the use of anticoagulant doses of heparin, but at present the optimal anticoagulant regimen remains to be determined.

APA, Harvard, Vancouver, ISO, and other styles

46

Patel, Lopa, and Rana Das Gupta. "Venous Thrombo-Embolic Prophylaxis in Aesthetic Surgery: A National Audit of Practices in the United Kingdom." Aesthetic Surgery Journal 38, no. 6 (2018): NP88—NP91. http://dx.doi.org/10.1093/asj/sjy007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

O'shaughnessy, Denise F. "Current Clinical Practice: Low-Molecular-Weight Heparins in The Prophylaxis and Treatment of Thrombo-Embolic Disease." Hematology 4, no. 5 (1999): 373–80. http://dx.doi.org/10.1080/10245332.1999.11746462.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Borgonovo dos Santos, Marcelo. "THROMBOSIS PROPHYLAXIS IN HAIR TRANSPLANT SURGERY." Arquivos Catarinenses de Medicina 52, no. 3 (2024): 54–62. https://doi.org/10.63845/kwve6t87.

Full text

Abstract:

Objective. The aim of this report is to present a cohesive evidence-based approach to reducing venous thromboembolism (VTE) in hair transplant surgeries. VTE prevention includes deep venous thrombosis and pulmonary embolism. Despite international efforts in VTE prevention, guidelines do not exist for hair transplant surgeries worldwide. Data source. PubMed/MEDLINE. Review Methods. A comprehensive review of literature to VTE in hair transplant surgery was performed, identifying data on incidence of thrombotic complications and the outcomes of regimens for thrombo-prophylaxis. No data were available, then we compared other surgical specialties. Conclusions. We identified 17 articles, including 3 prospective cohort studies, 3 retrospective studies, 1 case-control study, and 10 systematic review studies. We did not identify any study related to hair transplant. Of the 17 articles selected, 7 are related to prophylaxis of DVT, 4 related to plastic surgeries, 4 related to otolaryngology-head and neck surgeries and 2 related to elective surgeries. The overall prevalence of VTE in otolaryngology appears lower than that of most other surgical specialties. The Caprini system allows effective individualized risk stratification for VTE prevention in otolaryngology. Mechanical and chemoprophylaxis (‘‘dual thromboprophylaxis’’) is recommended for patients with a Caprini score 7 or patients with a Caprini score of 5 or 6 who undergo to long surgeries, where an increase in surgical duration was directly associated with an increase in the risk for VTE, and when prolonged hospital stay is anticipated or mobility is limited. For patients with a Caprini score of 5 or 6, we recommend dual thromboprophylaxis or mechanical prophylaxis alone. Patients with a Caprini score 4 should receive mechanical prophylaxis alone. These finding may help inform preoperative and postoperative decision making related to surgery.

APA, Harvard, Vancouver, ISO, and other styles

49

Hassan, Ahmed, TimourEl Husseiny, MahmoudEl Sebaie, et al. "EVALUATION OF VENOUS THROMBO-EMBOLISM PROPHYLAXIS IN PATIENTS UNDERGOING MAJOR ORTHOPEDIC SURGERIES (HIP & KNEE) IN EGYPT." International Journal of Advanced Research 5, no. 9 (2017): 104–13. http://dx.doi.org/10.21474/ijar01/5307.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Gericke, C. A., O. Boiko, S. Child, T. Nokes, A. Copplestone, and R. Sheaff. "PCV143 Implementation of Evidence-Based National Guidance on Venous Thrombo-Embolism Prophylaxis for Hospital Inpatients in England." Value in Health 14, no. 7 (2011): A390. http://dx.doi.org/10.1016/j.jval.2011.08.862.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!